NExT NX232-107-158-006 TO#3 Milestone 3 (base) - PK & Bioavail Stud w/Selected Anticancer Compounds in Mice, PK & Pharm Evals of Agents Being Developed for Cancer Patients, HHSN261201600024I/HHSN26100

下一个 NX232-107-158-006 至

• 批准号: 9576580
• 负责人: JOEL REID
• 金额: $ 1.67万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-07 至 2021-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9576580
• 关键词: Biological Availability; Cancer Patient; Data; Drug Kinetics; Mus; Plasma; base; small molecule

The purpose of this Task Order is to characterize the plasma pharmacokinetics (PK) and bioavailability of small molecule candidate anticancer compounds in mice in support of NExT project team(s). Rapid turn-around of study results is required. There are nine (9) options for additional studies under this task order. Delivery of a comprehensive spreadsheet (Excel) containing data for all compounds studied is required. This will allow the NExT project team to conduct a comprehensive analysis across compounds.

本课题的目的是研究小分子候选抗癌化合物在小鼠体内的血浆药代动力学(PK)和生物利用度，以支持NEXT项目团队(S)。需要迅速扭转研究结果。根据该任务顺序，有九(9)个选项可供选择进行额外的学习。需要提交一份全面的电子表格(Excel)，其中包含所有研究的化合物的数据。这将使下一个项目团队能够对化合物进行全面分析。